Edition:
United Kingdom

People: Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

5.80USD
4:38pm BST
Change (% chg)

$-0.06 (-1.02%)
Prev Close
$5.86
Open
$5.91
Day's High
$5.94
Day's Low
$5.75
Volume
6,950
Avg. Vol
21,190
52-wk High
$39.00
52-wk Low
$4.99

VanLent, Anne 

Ms. Anne M. VanLent has been appointed as Director of Onconova Therapeutics, Inc., effective July 25, 2013. She has served as President of AMV Advisors, a personal consulting firm providing strategic and financial services to companies in the greater life sciences sector, since May 2008. Ms. VanLent has also served as a director and chair of the audit committee of Biota Pharmaceuticals, Inc. since May 2013, Aegerion Pharmaceuticals, Inc. since April 2013 and Ocera Therapeutics, Inc. since March 2011. From December 2004 to May 2013, Ms. VanLent was a director of Integra Life Sciences Holding Corporation, serving as a member of the audit committee from December 2004 to May 2013 and as its chair from May 2006 to May 2012, as well as serving as a member of the compensation committee from 2005 to 2006. From 1998 to 2010, Ms. VanLent served as a director of Penwest Pharmaceuticals Co., where she was chair of the audit committee between 1999 and 2010 as well as chair of the nomination and governance committee from 2008 to 2010. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --